| 0.6546 0.042 (6.93%) | 07-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.81 | 1-year : | 0.89 |
| Resists | First : | 0.69 | Second : | 0.76 |
| Pivot price | 0.64  |
|||
| Supports | First : | 0.58 | Second : | 0.49 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.65 |
| MA(100) : | 0.63 |
MA(250) : | 0.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.2 |
D(3) : | 22.3 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 2.91 | Low : | 0.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BRNS ] has closed below upper band by 43.8%. Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.67 - 0.67 | 0.67 - 0.67 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.65 - 0.65 | 0.65 - 0.66 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Fri, 26 Jun 2026
BRNS Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 17 Jun 2026
Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mon, 11 May 2026
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
Thu, 30 Apr 2026
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - Yahoo Finance
Wed, 10 Dec 2025
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Yahoo Finance
Tue, 30 Sep 2025
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 19.8 (%) |
| Held by Institutions | 44.2 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -57.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|